There are, however, a small percentage of patients −20–40% in eAMD [4] and 15–20% in diabetic retinopathy [9,10]—who do not adequately or fully respond to anti-VEGF therapy and require alternate treatment strategies for their management. Here, VEGFA is linked to diabetic retinopathy.